Bluejay Diagnostics enters May having shed the short position built up during one of the most compressed stretches the stock has seen in over a year.
The defining move of the past six weeks was a dramatic unwinding of short interest, not a build. Short interest peaked at roughly 6.6% of the free float in late March, with shares-short sitting above 55,000. By April 30, that had collapsed to 0.84% of the float — an 87% decline from peak levels and the lowest reading in the entire 40-day window ORTEX tracks. The retreat accelerated sharply in the week of April 24, when shorts dropped from around 3% to below 1% in a single session. That is not a slow, orderly cover — it reads as forced or reactive.
The borrow market tells a story of ongoing friction, even as the position shrinks. Cost to borrow is running near 49% annualised — expensive for a micro-cap, and still well above the mid-30s range from mid-April despite a 26% decline from its March peak of over 73%. Availability has moved in the opposite direction. Borrow availability has eased alongside the short unwind — the lending pool is no longer stretched as it was when shorts held over 6% of float and the borrow hit its peak. The ORTEX short score ticked down to 49.4 by April 30, from a recent high of 54.1 on April 20, which is broadly neutral territory. Days to cover ranks in the 90th percentile of the universe, reflecting the micro-cap float rather than extreme crowding.
The analyst and valuation picture for BJDX is essentially absent. No recent analyst coverage or price targets are available, and valuation multiples are not meaningful given the company's negative enterprise value and the absence of meaningful revenue. Institutional ownership is concentrated — Anson Group holds 8.9% of shares, and Armistice Capital entered a 46,795-share new position in the December 2025 quarter, taking roughly 4.7%. Braeden Lichti's 35,500-share stake, reported in March 2026, adds further concentration among a very small holder base of twelve institutions in total. These are not passive index funds — they are typically active in small-cap and special-situation names, which makes their presence worth tracking.
Insider activity is stale. The last recorded trades date to December 2023, with a combined net of 1,000 shares purchased at roughly $3 apiece by the CEO and a director. There has been no insider activity in the 18 months since. Given the stock's current price of $1.92, those earlier purchases are underwater.
Recent earnings reactions have been modest and mixed — a 9% one-day gain on the April 2026 print, but a 4% five-day pullback, and a 8% one-day drop after the November 2025 result followed by an 18% five-day loss. No next earnings date is confirmed. Against that backdrop, the key development to watch is whether short interest stabilises at the current sub-1% level or creeps back up — a rebuild of the position, especially if accompanied by renewed borrow tightening above the 50% cost-to-borrow level, would mark a meaningful change in the setup.
See the live data behind this article on ORTEX.
Open BJDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
